An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors

Background: BXQ-350 is a novel anti-neoplastic agent composed of saposin C (SapC) and phospholipid dioleoylphosphatidyl-serine sodium (DOPS) that selectively binds tumor cell phosphatidylserine (PS), inducing apoptosis. BXQ-350 has demonstrated preclinical antitumor effects in high-grade gliomas (HG...

Descripció completa

Dades bibliogràfiques

Autors principals:	Mohamed S. Abdelbaki, Mariko Dawn DeWire Schottmiller, Timothy P. Cripe, Richard C. Curry, Charles A. Cruze, Leah Her, Suzanne Demko, Denise Casey, Bhuvana Setty
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2022-12-01
Col·lecció:	Heliyon
Matèries:	Pediatric oncology Tumors Brain Phase I clinical Trials Rare tumors
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2405844022037380
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!